ASH Annual Meeting & Exposition: Myelodysplastic Syndrome

In patients with VEXAS Syndrome with or without MDS, ESAs/luspatercept generated positive hematologic improvement-erythroid responses.

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).

For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.

Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found.